JPMorgan Chase & Co. Boosts Guardant Health (NASDAQ:GH) Price Target to $48.00

Guardant Health (NASDAQ:GH) had its target price lifted by JPMorgan Chase & Co. from $45.00 to $48.00 in a report issued on Thursday morning, Benzinga reports. They currently have an overweight rating on the stock.

GH has been the topic of a number of other reports. BTIG Research upped their target price on shares of Guardant Health from $45.00 to $50.00 and gave the company a buy rating in a report on Tuesday, July 30th. Canaccord Genuity Group upped their price target on shares of Guardant Health from $30.00 to $38.00 and gave the company a buy rating in a research note on Tuesday, June 4th. Craig Hallum upped their price target on shares of Guardant Health from $28.00 to $37.00 and gave the company a buy rating in a research note on Thursday. Bank of America upped their price target on shares of Guardant Health from $28.00 to $40.00 and gave the company a buy rating in a research note on Thursday, July 18th. Finally, Jefferies Financial Group assumed coverage on shares of Guardant Health in a research note on Monday, June 3rd. They issued a buy rating and a $32.00 price target on the stock. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of $39.00.

Guardant Health Stock Down 4.2 %

NASDAQ:GH traded down $1.27 on Thursday, hitting $29.00. 2,550,636 shares of the company’s stock were exchanged, compared to its average volume of 2,051,212. The firm has a 50-day moving average price of $30.59 and a 200-day moving average price of $24.02. The company has a debt-to-equity ratio of 16.70, a current ratio of 5.95 and a quick ratio of 5.66. Guardant Health has a 52 week low of $15.81 and a 52 week high of $41.06. The company has a market cap of $3.55 billion, a P/E ratio of -7.40 and a beta of 1.13.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.94). The company had revenue of $168.49 million for the quarter, compared to analysts’ expectations of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. As a group, analysts expect that Guardant Health will post -3.31 EPS for the current fiscal year.

Institutional Trading of Guardant Health

Several large investors have recently made changes to their positions in the company. Van ECK Associates Corp boosted its position in shares of Guardant Health by 29.4% during the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after acquiring an additional 614 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Guardant Health by 10.5% during the 4th quarter. Principal Financial Group Inc. now owns 13,045 shares of the company’s stock worth $353,000 after acquiring an additional 1,240 shares in the last quarter. Wealthcare Advisory Partners LLC boosted its position in shares of Guardant Health by 17.9% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 8,596 shares of the company’s stock worth $233,000 after acquiring an additional 1,308 shares in the last quarter. Oak Ridge Investments LLC boosted its position in shares of Guardant Health by 8.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company’s stock worth $382,000 after acquiring an additional 1,451 shares in the last quarter. Finally, Headlands Technologies LLC boosted its position in shares of Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after acquiring an additional 1,844 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.